Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPE-T Triple Therapy for Refractory Solid Tumors
NCT05438342Unknown
- Sponsor
- Shanghai Pudong Hospital
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in solid tumor (3 arms), sponsored by Shanghai Pudong Hospital. Primary endpoint: Progression-free survival at 12 months. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05438342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438342.